Ofloxacin plus cytotoxic chemotherapy which indicated no efficacy improvement

This value is similar to the 23,600 nmol 9 h/L that was observed Acadesine in the single agent study of enzastaurin at 525 mg orally daily . Likewise, in the current study, CLss/F was 53.8 L/h, which is not notably different from the CLss/F of 40.3 L/h in the previous study of single agent enzastaurin at 525 mg orally daily . Due to the high variability in CLss/F for both studies with at least SD. Given the tolerable toxicity profile and the lack of pharmacokinetic interactions, the combination of erlotinib and enzastaurin was explored further. The phase II portion of this trial was initiated in patients with NSCLC who had previously been treated with one or two prior chemotherapy regimens but had no prior exposure to an EGFR targeted agent.
Enzastaurin is a serine/threonine kinase inhibitor that targets protein kinase C and AKT pathways. Enzastaurin and pemetrexed demonstrated synergy in preclinical studies. This trial was designed to evaluate the safety and efficacy of first line enzastaurin plus cisplatin pemetrexed in advanced non small cell lung cancer . Ofloxacin clinical trial Methods: A safety lead in phase of enzastaurin 125 or 250 mg twice daily was added to cisplatin pemetrexed. A subsequent randomized, placebo controlled phase II study of the combination was conducted to evaluate efficacy. Results: The combination was well tolerated and showed activity, with 7 confirmed partial responses and 2 stable diseases in 13 treated patients in the lead in phase. However, the study was terminated early based on interim results from two phase II NSCLC studies of enzastaurin plus cytotoxic chemotherapy, which indicated no efficacy improvement.
Conclusions: Enzastaurin and cisplatin pemetrexed is tolerable with preliminary activity in patients with advanced Ofloxacin structure NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early.Guidelines regarding first line therapy for advanced non small cell lung cancer recommend a platinum plus third generation Ofloxacin solubility cytotoxic agent ; however, these regimens have shown a plateau in efficacy . The addition of newer signaling pathway targeted agents to current therapies may enhance the clinical efficacy of current therapies. Enzastaurin, an oral serine/threonine kinase inhibitor, targets both the protein kinase C and AKT pathways and induces tumor cell apoptosis, reduces proliferation and suppresses angiogenesis.
In preclinical lung cancer models, including NSCLC cell lines and xenografts, enzastaurin demonstrated anti angiogenic and anti tumor activity . In clinical studies, enzastaurin up to 700 mg daily was well tolerated and demonstrated promising activity in multiple tumor types . The multi targeted welfare state agent, pemetrexed, is approved in combination with cisplatin as first line therapy in advanced non squamous NSCLC . Preclinical results suggest that enzastaurin, in combination with pemetrexed, promotes synergistic growth inhibition of small cell lung cancer and NSCLC cell lines . In a phase IB study of enzastaurin in combination with pemetrexed, plasma exposure of enzastaurin and metabolites were increased when enzastaurin was administered as a 250 mg twice daily dose compared with a 500 mg QD dose. This increased exposure did not result in a significant.